Accessibility Menu
Invex Therapeutics logo

Invex Therapeutics(ASX) IXC

Market CapA$8.64MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-58%
5 Year-32%
1 Year+21%
1 Month+0%
A$0.12
+9.52%
+0.01Today
Invex Therapeutics last closing stock price
MetricPriceDate
Last closeAUD 0.122026-09-07
Invex Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+4.55%AUD 0.112026-08-31
1 month+0%AUD 0.122026-08-07
3 month+4.55%AUD 0.112026-06-05
Year to date-4.17%AUD 0.122025-12-30
1 year+21.05%AUD 0.102025-09-05
3 year+109.92%AUD 0.052023-09-07
5 year-32.13%AUD 0.172021-09-08
Since inception-58.02%AUD 0.272019-07-05

Invex Therapeutics Financials at a Glance

Market Cap

A$8.64MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$229.08K

Net Income (TTM)

-A$1.83M

EPS (TTM)

-A$0.02

P/E Ratio

-6.39

Dividend

A$0.00

Beta (Volatility)

0.07 (Low)

Price

A$0.12

Volume

0

Open

A$0.12

Previous Close

A$0.12

Daily Range

A$0.12 - A$0.12

52-Week Range

A$0.09 - A$0.18

Estimated Earnings Date

Feb 18, 2027

IXC News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Invex Therapeutics

Invex Therapeutics Ltd is an Australian biopharmaceutical company focused on developing innovative treatments for neurological disorders. The company primarily targets conditions associated with elevated intracranial pressure, utilizing Exenatide, which has shown promise in Phase II clinical trials.

Products and Services
  • Exenatide for treating idiopathic intracranial hypertension
  • Research and development of therapies for acute stroke
  • Innovative solutions for traumatic brain injury
Growth Outlook
  • Exenatide has advanced through Phase II clinical trials, indicating potential market readiness
  • Strong focus on neurological disorders presents significant market opportunities
  • Continued investment in R&D to enhance product pipeline and therapeutic options
Financial Highlights
  • Recent quarterly revenue of AUD 229,084, showing growth potential
  • Cash and cash equivalents of AUD 4,595,328, providing operational stability
  • Current ratio of 26.76, indicating strong liquidity position
Invex Therapeutics Ltd operates in the biotechnology sector, with a commitment to addressing unmet medical needs in neurology. The company has made significant strides in its clinical development, particularly with Exenatide, which is positioned to address serious health issues related to elevated intracranial pressure. The financial metrics reflect a solid liquidity position, which is crucial for ongoing research and development efforts. With a focus on innovative therapies and a robust pipeline, Invex Therapeutics Ltd presents an intriguing opportunity for investors interested in the biopharmaceutical landscape.
AI Generated • Aug 17, 2026

Industry

Pharmaceuticals

Sector

Health Care

Website

www.invextherapeutics.com

Headquarters

Subiaco, WA 6008, AU

IXC Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-31.98%

Return on Capital

-39.50%

Return on Assets

-33.28%

Earnings Yield

-15.65%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$8.64MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

75.15M

Volume

0

Avg. Volume

33.46K

Financials (TTM)

Gross Profit

A$229.08K

Operating Income

-A$2.25M

EBITDA

-A$1.90M

Operating Cash Flow

-A$1.56M

Capital Expenditure

A$0.00

Free Cash Flow

-A$1.56M

Cash & ST Invst.

A$4.02M

Total Debt

A$0.00

Invex Therapeutics Performance Analysis

Invex Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 0N/A
20242024-06-30AUD 0N/A
20252025-06-30AUD 0N/A
20262026-06-30AUD 0N/A
Invex Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31-100.0%
Q42025-06-30N/A
Q22025-12-31-100.0%
Q42026-06-30N/A
Invex Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD -0.1096.0%
20242024-06-30AUD -0.02-78.9%
20252025-06-30AUD -0.01-70.6%
20262026-06-30AUD -0.02181.2%
Invex Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31-175.8%
Q42025-06-3066.0%
Q22025-12-31-493.7%
Q42026-06-3010.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$0.00

-100.0%

Gross Profit

A$0.00

-100.0%

Gross Margin

0.00%

N/A

Market Cap

A$8.64MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$2.16M

N/A

Employees

4

N/A

Net Income

-A$636.77K

-235.2%

EBITDA

-A$701.40K

+5.3%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$4.02M

-33.3%

Total Debt

A$0.00

N/A

Accounts Receivable

A$47.33K

-50.2%

Inventory

A$0.00

N/A

Long Term Debt

A$0.00

N/A

Short Term Debt

A$0.00

N/A

Return on Assets

-33.28%

N/A

Return on Invested Capital

-39.50%

N/A

Free Cash Flow

-A$779.73K

+66.4%

Operating Cash Flow

-A$779.73K

+66.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
VBS.AXVectus Biosystems Limited
A$0.17+0.00%
ACR.AXAcrux Limited
A$0.01+0.00%
ICR.AXIntelicare Holdings Limited
A$0.03+0.00%
BGT.AXBio-Gene Technology Limited
A$0.02+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$46.34-0.10%
NOKNokia
$10.03+0.03%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$117.28+0.10%
INTCIntel
$95.80+0.05%

Questions About IXC

What is the current price of Invex Therapeutics?

Invex Therapeutics is trading at A$0.12 per share.

What is the 52-week range for Invex Therapeutics?

Over the past 52 weeks, Invex Therapeutics has traded between A$0.09 and A$0.18.

How much debt does Invex Therapeutics have?

As of the most recent reporting period, Invex Therapeutics reported total debt of A$0.00.

How much cash does Invex Therapeutics have on hand?

Invex Therapeutics reported A$1.52M in cash and cash equivalents in its most recent financial results.

What is Invex Therapeutics’s dividend yield?

Invex Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services